ProBio在新泽西州霍普韦尔开设美国旗舰质粒和病毒载体制造工厂，以推进细胞和基因治疗-动脉网

ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy

CISION 等信源发布 2025-06-27 18:30



可切换为仅中文







HOPEWELL, N.J.

霍普韦尔，新泽西州

，

June 27, 2025

2025年6月27日

/PRNewswire/ --

ProBio

普罗拜奥

, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its flagship

，一家全球合同开发和制造组织（CDMO），专注于细胞和基因治疗，今天宣布其旗舰工厂的开业

Cell and Gene Therapy Center of Excellence

细胞与基因治疗卓越中心

at the Princeton West Innovation Campus in

普林斯顿西创新园区位于

Hopewell, New Jersey

霍普韦尔，新泽西州

. The 128,000 sq ft GMP facility is purpose-built for manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms, reflecting ProBio's dedication to accelerating the delivery of transformative medicines.

这座占地128,000平方英尺的GMP设施专为生产高质量的质粒DNA和病毒载体而建，包括腺相关病毒（AAV）和慢病毒载体（LVV）平台，体现了ProBio致力于加速转化药物的交付。

From left to right — Kristen Foca (Office of Senator Andy  Kim), John Coelho (NJEDA), Michael Vreeland (Site Head, ProBio Hopewell), Allen Guo (CEO, ProBio), Frank Zhang (Founder of GenScript Corporation, Chairman of Legend Bio), Courtney Peters‑Manning (Mayor of Hopewell Township), Debbie Hart (CEO, BioNJ), and Kevin Kuchinski (Township Committee Member) — join forces to officially cut the ribbon, marking the launch of ProBio’s Cell and Gene Therapy Center of Excellence in Hopewell, New Jersey.

从左到右 —— 克里斯汀·福卡（参议员安迪·金办公室）、约翰·科埃略（新泽西经济发展局）、迈克尔·弗里兰（普罗生物霍普韦尔基地负责人）、郭艾伦（普罗生物首席执行官）、张峰（金斯瑞创始人、传奇生物董事长）、考特尼·彼得斯-曼宁（霍普韦尔镇市长）、黛比·哈特（BioNJ首席执行官）和凯文·库钦斯基（镇议会成员）——共同为普罗生物在新泽西州霍普韦尔的细胞与基因治疗卓越中心正式剪彩，标志着该中心正式启动。

ProBio, led by Allen Guo (CEO) and Michael Vreeland (U.S. Site Head), celebrates the grand opening of its Cell & Gene Therapy Center of Excellence in Hopewell. Team members gathered to mark this milestone, highlighting ProBio’s commitment to innovation, the creation of over 110 high-skilled jobs, and the advancement of New Jersey’s biomanufacturing ecosystem..

ProBio在霍普韦尔举行其细胞与基因治疗卓越中心的盛大开幕仪式，公司由郭华（首席执行官）和迈克尔·弗里兰（美国站点负责人）领导。团队成员齐聚一堂，共同庆祝这一里程碑，彰显了ProBio对创新的承诺、创造超过110个高技能工作岗位，以及推动新泽西州生物制造生态系统的发展。

Frank Zhang, Founder of GenScript and Chairman of Legend Biotech, delivers opening remarks at the ProBio Hopewell ribbon-cutting ceremony, highlighting the company’s global vision and commitment to advancing cell and gene therapy manufacturing.

张峰，金斯瑞创始人兼传奇生物董事长，在ProBio Hopewell剪彩仪式上致开幕词，强调了公司推动细胞和基因治疗制造的全球愿景与承诺。

Donavon Decker, the world’s first gene therapy recipient for muscular dystrophy, delivers a powerful virtual keynote at ProBio’s grand opening. His story underscored the life-changing potential of advanced therapies and the vital role ProBio’s Hopewell facility will play in accelerating access for patients worldwide..

唐纳文·德克尔，世界上首位接受基因治疗的肌肉萎缩症患者，在ProBio盛大开幕仪式上发表了一场有力的虚拟主题演讲。他的故事强调了先进疗法改变生活的潜力，以及ProBio的霍普韦尔设施在加速全球患者获取治疗方面将发挥的关键作用。

'This is not just a new facility. It is a beacon of hope for patients waiting for cures,' said Allen Guo, CEO of ProBio.

“这不仅仅是一个新设施。对于等待治愈的患者来说，它是一座希望的灯塔，”ProBio首席执行官郭华说。

Post this

发布这个

The celebration included an open house event featuring a guided site tour, ribbon-cutting ceremony, and a keynote address by

庆祝活动包括一个开放日活动，活动内容有现场导览、剪彩仪式以及主题演讲。

Donavon Decker

多纳文·德克尔

, the first person in the world to receive gene therapy for any form of muscular dystrophy in 1999. Decker shared his experience from that landmark trial at Ohio State University—led by Dr. Jerry Mendell—and spoke movingly about how state-of-the-art facilities like ProBio's

，是1999年世界上第一位接受任何形式肌肉萎缩症基因治疗的人。德克尔在俄亥俄州立大学分享了他从这一里程碑试验中的经历，该试验由杰里·门德尔博士领导，并感人地谈到了像ProBio这样的最先进的设施如何改变了局面。

Hopewell

霍普韦尔

site help translate scientific advances into real patient outcomes.

现场帮助将科学进展转化为真实的患者结果。

The ribbon-cutting ceremony featured remarks from prominent leaders:

剪彩仪式上，杰出的领导人发表了讲话：

Debbie Hart

黛比·哈特

, CEO of BioNJ; Courtney Peters–Manning, Mayor of

，BioNJ首席执行官；Courtney Peters-Manning，市长

Hopewell Township

霍普韦尔镇

;

；

John Coelho

约翰·科埃略

of the New Jersey Economic Development Authority (NJEDA);

新泽西经济发展局 (NJEDA)；

Michael Vreeland

迈克尔·弗里兰

, Site Head of ProBio Hopewell;

普罗生物霍普韦尔基地负责人；

Allen Guo

郭艾伦

, CEO of ProBio; and

，ProBio首席执行官；以及

Frank Zhang

张锋

, Founder of GenScript and Chairman of Legend Biotech.

金斯瑞创始人、传奇生物董事长。

Mayor

市长

Courtney Peters-Manning

考特尼·彼得斯-曼宁

welcomed the company warmly, stating: '

热情地欢迎了公司，表示：

Hopewell Township

霍普韦尔镇

is a wonderful place to live and work, and we are thrilled to welcome ProBio to our community, where they will make cutting-edge, life-changing therapies, in addition to creating high-skilled jobs.'

“是一个生活和工作的好地方，我们非常欢迎ProBio加入我们的社区，他们将在这里研发尖端的、改变生命的疗法，同时创造高技能的工作岗位。”

John Coelho

约翰·科埃略

of NJEDA

新泽西经济发展局

emphasized the strategic significance of the opening: 'The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring

强调了此次开业的战略意义：“ProBio 作为一家最先进的、完全集成的端到端合同开发和制造组织，其开业将极大地促进细胞和基因生物制品的开发及生物制造生态系统的发展，成为该领域的核心。”

New Jersey

新泽西州

as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.'

作为该领域的领导者，支持全球临床试验注册的生产能力以及靠近领先的精准医疗中心，将使突破性药物能更快地送达患者手中。'

Built to meet the most rigorous GMP standards, the

为满足最严格的GMP标准而建造，

Hopewell

霍普韦尔

site is equipped to support clinical-stage development, process-development and scale-up for cell and gene therapy programs. This capability solidifies

该站点具备支持细胞和基因治疗项目的临床阶段开发、工艺开发和规模扩大的能力。这一能力巩固了

New Jersey's

新泽西州的

position as a leader in biopharmaceutical manufacturing. During the open house, guests toured advanced GMP suites and production lines, and engaged with ProBio's scientific and operations teams as well as industry, academic, and government partners.

在生物制药生产领域的领导地位。在开放日活动中，嘉宾们参观了先进的 GMP 套房和生产线，并与普罗生物的科学和运营团队以及行业、学术界和政府合作伙伴进行了交流。

'This is not just a new facility. It is a beacon of hope for patients waiting for cures,' said

“这不仅仅是一个新设施。它为等待治愈的患者带来了希望的曙光，”

Allen Guo, CEO of ProBio.

郭炳联，ProBio首席执行官。

'Opening the

'开启

Hopewell

霍普韦尔

center is a milestone in ProBio's global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.'

中心是ProBio全球扩张的一个里程碑，突显了我们通过高质量、响应迅速的制造解决方案支持生物制药创新者的使命。

Bringing over 110 high-skilled jobs to

带来超过110个高技能工作岗位

New Jersey

新泽西州

, ProBio's

，ProBio的

Hopewell

霍普韦尔

facility continues to expand its capabilities. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site.

设施能力持续扩展。GMP AAV生产预计将在2025年第三季度启动，而GMP LVV服务则将在2026年第一季度跟进——从而在一个集成场地内为更广泛的治疗候选药物提供支持，涵盖从早期概念验证到临床准备的全过程。

Located in the heart of

位于中心地带

New Jersey's

新泽西州的

rapidly expanding innovation corridor, ProBio's

快速扩展的创新走廊，ProBio的

Hopewell

霍普韦尔

facility serves as the company's North American hub, designed to support and complement its broader operations across

该设施作为公司北美枢纽，旨在支持和补充其在北美的更广泛业务运营。

North America

北美

and

和

Europe

欧洲

. This strategic investment aligns with efforts to strengthen transatlantic biomanufacturing capacity and resilience—positioning the site to meet growing demand for advanced therapeutic production across both continents.

这一战略性投资符合加强跨大西洋生物制造能力和韧性的努力——使该基地能够满足两大洲对先进治疗生产不断增长的需求。

For more information about ProBio and its full suite of development and manufacturing services, please visit

有关 ProBio 及其全套开发和制造服务的更多信息，请访问

www.probiocdmo.com

。

ABOUT PROBIO

关于PROBIO

ProBio is a global leader in advancing the development and manufacturing of next generation biologics and advanced therapies for the biotech and pharmaceutical industries. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with its clients to optimize drug development, accelerate time-to-market, and provide comprehensive life-cycle support. .

ProBio 是生物技术和制药行业下一代生物制品和先进疗法开发与制造的全球领导者。作为一家完全集成的端到端合同开发和制造组织 (CDMO)，ProBio 与客户合作，优化药物开发、加快上市时间，并提供全面的生命周期支持。

Through a collaborative, risk-sharing approach, ProBio offers flexible licensing and co-development options for new therapeutics, enabling partners to effectively navigate the complexities of human disease with adaptable, cutting-edge therapeutic approaches.

通过合作、共担风险的方式，ProBio 为新型治疗药物提供灵活的许可和共同开发选项，使合作伙伴能够以适应性强、尖端的治疗方法有效应对人类疾病的复杂性。

To learn more about ProBio services, please visit

要了解有关ProBio服务的更多信息，请访问

https://www.probiocdmo.com/

。

CUSTOMIZED CDMO SOLUTIONS. DEVELOPED FASTER. DELIVERED BETTER.

定制的CDMO解决方案。开发更快。交付更好。

Media Contact:

媒体联系人：

Alvin Jogasuria

阿尔文·乔加苏里亚

Head of Marketing, Americas and